Actively Recruiting
REsiduAL rISk Under Intensive Lipid-lowering Therapy In Coronary Heart Disease
Led by Shanghai Zhongshan Hospital · Updated on 2026-02-03
900
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Intensive lipid-lowering therapy is a cornerstone treatment for coronary heart disease (CHD). However, coronary plaque progression persists in a subset of patients even under intensive lipid-lowering therapy, which may be associated with residual lipid and inflammatory risks. Current research in this area remains largely confined to post hoc analyses of randomized controlled trials , with a notable scarcity of prospective follow-up cohorts. The investigators propose that establishing a prospective cohort will provide more authentic insights into the associations between residual risk factors and plaque progression. In this project, the investigators aim to establish a well-characterized CHD cohort with comprehensive data collection, good compliance, and an appropriate sample size. By focusing on non-target lesions within the target vessel and utilizing intravascular ultrasound (IVUS), the investigators will investigate the impact of residual lipid and inflammatory risks on plaque progression during intensive lipid-lowering therapy.
CONDITIONS
Official Title
REsiduAL rISk Under Intensive Lipid-lowering Therapy In Coronary Heart Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with coronary artery disease and have had successful PCI
- Presence of non-target lesions near the target lesion with 20% to 50% stenosis and identifiable anatomical markers
- Aged between 18 and 75 years
- Provided written informed consent
You will not qualify if you...
- Known autoimmune diseases or long-term use of immunosuppressive drugs
- Known familial hypercholesterolemia
- Critical conditions such as cardiogenic shock or acute heart failure
- Severe kidney failure (eGFR < 30 mL/min/1.73m2) or severe liver dysfunction (ALT or AST 63;3 times upper limit of normal)
- Severe underlying diseases like end-stage malignancies with life expectancy less than 1 year
- Allergy to lipid-lowering medications
- Pregnant, trying to become pregnant, or breastfeeding
- Other conditions considered unsuitable by the researcher
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai Zhongshan Hospital
Shanghai, China
Actively Recruiting
Research Team
C
Chunfeng Dai, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here